← 返回

Pellino1-PKCθ 信号轴是改善抗肿瘤 CD8+ T 淋巴细胞功能的关键靶点

英文原题:The Pellino1-PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function.

查看英文原题

The Pellino1-PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function.

PubMed 2022/03/01(内容时间) Cancer Immunol Res Q1 · IF 7.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CD8阳性T细胞在清除肿瘤中发挥重要作用,但其效应应答如何被诱导并维持,相关机制仍有待阐明。Pellino1(Peli1)是一种响应受体信号的泛素E3连接酶,是先天免疫的重要介质。

本研究发现,肿瘤发生风险取决于Peli1表达。Peli1在TIL(肿瘤浸润淋巴细胞)中的CD8阳性T细胞内上调;相反,Peli1缺失可增强CD8阳性TIL的维持能力和效应功能。缺乏Peli1的CD8阳性TIL发育可防止T细胞耗竭,并使T细胞保持过度活化状态以清除肿瘤。研究还发现,Peli1可直接与蛋白激酶C-θ(PKCθ)相互作用;PKCθ是T细胞受体下游信号转导的核心激酶,但其在肿瘤免疫学中的作用尚不清楚。Peli1通过赖氨酸48介导的泛素化降解,抑制CD8阳性TIL中的PKCθ通路。

综上,Peli1-PKCθ信号轴是一种共同的抑制机制,会阻碍CD8阳性T细胞发挥抗肿瘤功能,因此靶向Peli1可能是增强细胞毒性T细胞活性的有效治疗策略。

展开英文摘要原文

CD8+ T cells play an important role in the elimination of tumors.

However, the underlying mechanisms involved in eliciting and maintaining effector responses in CD8+ T cells remain to be elucidated. Pellino1 (Peli1) is a receptor signal-responsive ubiquitin E3 ligase, which acts as a critical mediator for innate immunity.

Here, we found that the risk of developing tumors was dependent on Peli1 expression. Peli1 was upregulated in CD8+ T cells among tumor-infiltrating lymphocytes (TIL). In contrast, a deficit of Peli1 enhanced the maintenance and effector function of CD8+ TILs. The development of Peli1-deficient CD8+ TILs prevented T-cell exhaustion and retained the hyperactivated states of T cells to eliminate tumors.

We also found that Peli1 directly interacted with protein kinase C-theta (PKC ), a central kinase in T-cell receptor downstream signal transduction, but whose role in tumor immunology remains unknown. Peli1 inhibited the PKC pathway by lysine 48-mediated ubiquitination degradation in CD8+ TILs. In summary, the Peli1-PKC signaling axis is a common inhibitory mechanism that prevents antitumor CD8+ T-cell function, and thus targeting Peli1 may be a useful therapeutic strategy for improving cytotoxic T-cell activity.

论文信息

作者
Park J、Lee SY、Jeon Y、Kim KM、Lee JK、Ko J、Park EJ、Yoon JS
单位
Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.South Korea
文献类型
非美国政府资助研究
期刊
Cancer immunology research2022 Mar 1
原文标识
PubMed 35058288 · DOI 10.1158/2326-6066.CIR-21-0419